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Abstract
Although anatomical imaging modalities (X-ray, computed tomography 
(CT), magnetic resonance imaging (MRI)) still have a higher spatial resolution 
(0.1–1 mm) than molecular imaging modalities (single-photon emission computed 
tomography (SPECT), positron emission tomography (PET), optical imaging 
(OI)), the advantage of molecular imaging is that it can detect molecular and 
cellular changes at the onset of a disease before it leads to morphological tissue 
changes, which can be detected by anatomical imaging. During the last decades, 
noninvasive diagnostic imaging has encountered a rapid growth due to the develop-
ment of dedicated imaging equipment for preclinical animal studies. In addition, 
the introduction of multimodality imaging (PET/CT, SPECT/CT, PET/MRI) which 
combines high-resolution conventional anatomical imaging with high sensitivity of 
tracer-based molecular imaging techniques has led to successful accomplishments 
in this exciting field. In this book chapter, we will focus on chemical synthesis 
techniques for site-specific incorporation of radionuclide chelators. Subsequently, 
radiolabeling based on complexation of a radionuclide with a chelator will be 
discussed, with focus on: diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tet-
raazacyclododecane-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-triacetic 
acid (NOTA), hexa-histidine (His-tag), and 6-hydrazinonicotinic acid (HYNIC) 
that allow the production of peptides labeled with 18F, 68Ga, 99mTc, and 111In – the 
currently most widely used isotopes.
Keywords: radiolabeled peptides, chelator, PET, SPECT, radionuclide,  
peptide synthesis, protein synthesis
1. Introduction
1.1 Application of peptides and proteins as molecular imaging agents
The concept of using radiolabeled receptor-binding peptides and proteins 
to target receptor-(over)expressing tissues in vivo has stimulated a large body 
of research in nuclear medicine. Peptides and small proteins for receptor imag-
ing and targeted radiotherapy have particular advantages over antibodies and 
antibody fragments. Peptides are small molecules and show rapid diffusion in 
target tissue. They rapidly clear from the blood and non-target tissues, resulting 
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in high target-to-background ratios. Furthermore, peptides have a low toxicity 
and are generally not immunogenic. However, ubiquitously occurring amino- and 
carboxypeptidases in the circulation will rapidly degrade most peptides prevent-
ing intact imaging agents to reach the target tissue in sufficient quantities. Thus, 
to prevent rapid enzymatic degradation of peptide-based imaging agents, most 
peptides have to be modified [1, 2]. Several methods to prevent enzymatic peptide 
proteolysis have been developed, including substitution of L- by D-amino acids, 
replacement of amino moieties by imino groups, substitution of peptide bonds, 
insertion of unusual amino acids or side chains, amidation, cyclization, C-terminal 
amidation or reduction, N-terminal acylation or methylation, and use of pepti-
domimetics. Cyclization of peptides results not only in resistance to enzymatic 
degradation, it can also lead to conformationally more constrained compounds 
with enhanced receptor affinity and biological activity [1, 3].
Besides stability toward enzymes, lipophilicity is very important. The preferred 
route of clearance of a peptide-based radiopharmaceutical is via the kidneys. For 
targeting of tumors, cardiovascular diseases, and infections or inflammation, 
the lipophilicity of the compound should not be too high (log P < 1) as lipophilic 
compounds result in non-specific binding and slower blood clearance via mainly 
the hepatobiliary route. In contrast, molecular imaging tracers that target brain 
diseases such as Alzheimer require a higher lipophilicity (log P > 1) in order to cross 
the blood–brain barrier (BBB). Lipophilicity of molecular imaging tracers can be 
reduced by linking them to polyethylene glycol (PEG) chains, a technique called 
PEGylation. An alternative method to reduce lipophilicity of a tracer is attachment 
of carbohydrates, as this enhances the hydrophilicity, resulting in reduced hepatobi-
liary uptake, enhanced urinary excretion, and reduced nonspecific binding [4].
Furthermore, conjugation of chelators like DOTA (1,4,7,10-tetraazacyclodo-
decane-tetraacetic acid), NOTA (1,4,7-triazacyclononane-triacetic acid), or DTPA 
(diethylenetriaminepentaacetic acid) also reduce the lipophilicity of an imaging 
agent. However, modification of a tracer by for example PEGylation, glycosylation 
or conjugation to a chelator, can also affect the affinity of a peptide for the receptor 
and thus the effectiveness of the radiotracer.
1.2  Introduction of bifunctional chelating agents (BFCAs) into the peptide or 
protein
A chelating agent will not only influence the hydrophilicity of a peptide or 
protein, but it will also increase the overall size of the radiotracer and thus the 
pharmacokinetics. To preserve biological activity and receptor-binding affinity, 
conjugation of a chelator must be performed at a site remote from the active and 
receptor-binding region of the tracer [5]. Total chemical protein synthesis enables 
single site-specific protein modification, which cannot be achieved through regular 
labeling methods of biologically obtained proteins. To prevent interference of the 
chelator with the active and receptor-binding region of the peptide, introduction of 
a linker may be necessary. These linkers (PEG chains, amino acids, aliphatic hydro-
carbon chains, etc.) can be used as pharmacokinetic modifiers (PKMs) to adjust the 
pharmacokinetics of the probe.
Several acyclic and cyclic bifunctional chelators have been developed for both 
diagnostic and therapeutic applications (Figure 1). A bifunctional chelator is a 
molecule which can be covalently coupled to the targeting compound and has the 
ability to chelate a (radio)metal. The most widely used chelators are DTPA, DOTA, 
and NOTA or derivatives thereof. A chelator should effectively sequester the radio-
nuclide in high-yields (quantitative) and with high stability. Unstable complexation 
of the radionuclide by the chelator can lead to trans-chelation of the radionuclide 
3
Strategies for Site-Specific Radiolabeling of Peptides and Proteins
DOI: http://dx.doi.org/10.5772/intechopen.99422
to blood proteins and enzymes (e.g. transferrin, ceruloplasmin, superoxide dis-
mutase). For a detailed review of chelating agents and the optimal match between 
chelator and radionuclide see Price et al. 2014 [6] and references therein.
The introduction of BFCA in proteins or peptides can be achieved using bio-
conjugation methods based on reactive functional groups, such as amide coupling 
(carboxylic acids and their activated N-hydroxysuccinimide (NHS) esters), thiol 
couplings (maleimides), oxime bond formation (ketones or aldehydes with ami-
nooxy), and Cu(I) catalyzed azide-alkyne Huisgen 1,3-dipolar cycloaddition “click 
reactions”. We will discuss some of the methods in detail in Section 2.3.
1.3 Radionuclide imaging
Apart from planar imaging, SPECT and PET are the two main imaging modali-
ties in nuclear medicine. SPECT imaging is much more widely available than PET 
imaging and the radionuclides used for SPECT are easier to prepare, financially 
generally more accessible, and usually have a longer half-life than those used for 
PET (Table 1). Commonly used gamma emitters are: 123I (Emax 529 keV, t1/2 13.0 h), 
111In (Emax 245 keV, t1/2 67.2 h), and 
99mTc (Emax 141 keV, t1/2 6.02 h). Compared 
to SPECT, PET has the possibility to more accurately quantitate the in vivo con-
centration of a tracer labeled with a positron emitting radionuclide, such as for 
(pre)clinical applications 18F (Emax 635 keV, t1/2 1.83 h), 
68Ga (Emax 1.90 MeV, t1/2 
68.1 min), 64Cu (657 keV, t1/2 12.7 h), and 
124I (Emax 2.13 MeV; 1.53 MeV; 808 keV, t1/2 
4.18 days).
PET is independent of the location depth of the reporter probe of interest and is 
able to detect picomolar concentrations of tracer [7]. This high sensitivity of PET 
can only be matched to some degree by optical imaging (OI) techniques, but not 
by MRI, CT or ultrasound (US). In addition, compared to MRI and conventional 
optical imaging techniques, PET has the advantage of being quantitative. Though, 
with the introduction of fluorescence mediated tomography (FMT), quantitative 
measurements are also possible with OI techniques [8].
Figure 1. 
Structural formula of different chelators and co-ligands for radiolabeling peptides and proteins.
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Recent developments also allow semi-quantitative measurements with SPECT, 
but these developments are not yet widespread and still show higher uncertainties 
compared to PET.
The spatial resolution of PET and SPECT scanners depends on several factors: 
the type of isotope (PET or SPECT), the energy of the isotope emissions, and the 
object being scanned. The type of isotope (positron-emitting or single-photon 
emitting) has a strong impact, as the image reconstruction techniques for PET 
are superior to those of SPECT due to physical characteristics in large objects, but 
this is reversed for small objects. The energy of the isotope emissions is negatively 
correlated to the spatial resolution: the stronger the energy, the poorer the spatial 
resolution. The object being scanned has a substantial impact: spatial resolution in 
mice is vastly superior to that in humans, and even within humans spatial resolution 
in obese people is worse compared to healthy subjects. Some typical spatial resolu-
tions are: 99mTc, mouse: 0.5 mm; 99mTc, human: 10 mm; 18F, mouse: 0.8 mm; 18F, 
human: 2 mm; 68Ga, human and mouse: both 4 mm. The spatial resolution should 
be taken into account when designing studies.
2. Peptide and protein synthesis
2.1 Protein production by expression systems
Nowadays, recombinant protein expression is a routine laboratory technology 
that enables fast and high-yield protein production. The choice of bacterial, yeast, 
insect or mammalian cellular-based expression system depends on several factors 
such as, cell growth characteristics, intracellular and extracellular expression, 
posttranslational modifications, and regulatory issues of proteins used as diagnos-
tics and therapeutics. Recently, even cell-free expression systems using purified 
RNA polymerase, ribosomes, tRNA and ribonucleotides have been developed [9]. 
Each expression system has its particular advantages and disadvantages that are 
relevant for the purpose of use. Several review papers give a good description of the 
Isotope Half-life (h) Decay type
γ-emitter (SPECT) 99mTc 6.02 IT
111ln 67.2 EC, γ
123l 13.0 EC, γ, e−
β+-emitter (PET) 18F 1.83 β+, EC
64Cu 12.9 β−, EC
68Ga 1.14 β+, EC
124l 76.8 EC, β+, γ
β−-emitter (therapy) 90Y 64.1 β−
177Lu 161 β−
186Re 91 β−, EC, γ
188Re 17.0 β−
131l 192 β−, γ, e−
Half-life is given in hours, unless stated otherwise. β− = negative beta decay, β+ = positive beta decay, γ = gamma 
transition, IT = isometric transition, EC = electron capture.
Table 1. 
Half-life and decay type of several radionuclides.
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variety of expression systems and their pros and cons. However, for development of 
target-specific radiotracers, fluorescent probes, or multimodality molecular imag-
ing agents, chemical protein synthesis is the method of choice because of reasons 
described below. Therefore, this book chapter does not cover recombinant expres-
sion systems further.
2.2 Solid-phase peptide synthesis
Total chemical protein synthesis is an attractive alternative to biological protein 
production. Chemical peptide synthesis can be divided in: (I) liquid-phase peptide 
synthesis and (II) solid-phase peptide synthesis. Liquid-phase peptide synthesis is a 
classical approach to peptide synthesis and since the beginning of the 20th century 
this technique has developed considerably. Although liquid-phase peptide synthesis 
has some limitations due to its time consuming nature, solubility issues and the 
need for lengthy purification procedures, it is still useful for large-scale peptide 
production and for specialized laboratory applications [10].
Solid-phase peptide synthesis (SPPS) is currently the preferential technique 
to establish access to synthetic peptides. The general process for SPPS is based on 
sequential addition of α-amino and reactive side chain protected amino acids to 
a solid support (resin). The C-terminal residue is coupled to the resin and after 
removal of the Nα-protecting group, the next C-terminally activated Nα-protected 
amino acid is coupled and so on, until full chain assembly is reached. The most 
commonly used Nα-protecting groups are the acid-labile Boc (tert-butyloxycar-
bonyl) group and the base-labile Fmoc (9-fluorenylmethoxycarbonyl) group. Side 
chain protecting groups are ideally orthogonal to the Nα-protecting group, which 
means that they are removable under completely different reaction conditions.
The use of synthetic chemistry allows infinite variation of the polypeptide chain 
by for example incorporation of unnatural amino acids such as β-amino acids, 
N-methyl amino acids, peptoids, stable isotope-labeled amino acids, and D-amino 
acids. Furthermore, the use of orthogonal amino acid side chain protecting groups 
during the sequential elongation of the peptide chain in SPPS, allows conjugation 
of fluorescent tags, chelators, biotin, etc., at single specific sites. Current optimized 
SPPS chemistry protocols enable effective peptide synthesis of 30–50 amino acids. 
For the synthesis of peptides and proteins bigger than 30–50 amino acids, various 
chemical ligation techniques were developed that enable the formation of a peptide 
bond between two unprotected peptides resulting in larger synthetic proteins with a 
fully native peptide backbone [11, 12].
2.3 Site-specific incorporation of chelators and/or fluorescent tags
Functionalization of peptides and proteins still heavily relies on amine or thiol 
functionalities, present in proteins as lysine and cysteine side chains, respectively. 
New ligation techniques are emerging that are moving away from amines or use 
of protected thiols. The functionalization of lysine side chains can be achieved by 
reacting them with activated esters such as NHS-DTPA or –DOTA that are commer-
cially available (Figure 2). The most appropriate derivatives of these chelators for 
conjugation to a peptide or protein are those which are tBu (tert-butyl)-protected at 
all functional acid groups, except one. This acid group can either be activated in situ 
using a proper coupling agent or be obtained as a preactivated NHS ester in DOTA-
tris(tBu)ester NHS ester, NOTA-bis(tBu) ester NHS ester, or DTPA-tetrakis(tBu) 
ester NHS ester.
The main advantage of these activated ester chelators is their ease of use, while 




Deprotection of thiazolidinecarboxyl coupled to Nε-amine group of a lysine residue using methoxylamine.
generally contains more than one lysine residue and thus more than one position 
for chelator conjugation. It is difficult to predict the site of coupling, which will 
often lead to heterogenous labeling of the compound of interest. With the use of 
Boc SPPS this problem can be circumvented by using orthogonally ε-amino Fmoc-
protected lysine residues. Deprotection of the Fmoc group can be performed on 
resin and directly be followed by functionalization of the desired lysine with an 
NHS-activated label of choice. In case of Fmoc SPPS, orthogonally ε-amino ally-
loxycarbonyl (Alloc) protected lysine residues can be used.
Conjugation at cysteine residues can be realized by reactions with maleimide 
containing compounds or 2-azidoacrylate-derivatives [13]. Similar to the amine 
reactive NHS esters, commercial compounds with maleimides are widespread. 
Maleimide-DOTA or –DTPA are coupled to free cysteine-containing proteins 
(Figure 3). Although the reaction is specific and easy to use, maleimides have 
their disadvantages. The first being the availability of a free cysteine in a protein 
of interest; the major part of cysteines present in proteins are paired with a 
second cysteine to form a disulfide bridge. Moreover, these cysteines are often 
buried within the core of the protein making them inaccessible for maleimides. To 
overcome this problem an additional cysteine can be incorporated into the protein 
specifically for labeling. This will, however, lead to problems with oxidative fold-
ing of the protein and can lead to improperly folded proteins with loss of activity.
However, this does not mean that thiol reactive compounds cannot be useful in 
protein labeling. The introduction of an encrypted cysteine that can be deprotected 
after correct folding of the protein can offer a solution. Recently Nε-(thiazolidine 
carboxyl)-lysine was applied for this purpose [14], the thiazolidine carboxylic acid 
(Thz) that was originally designed to facilitate sequential one-pot native chemical 
ligation (NCL) [15–17], was used as a handle for late stage site-specific modification 
of proteins under mild conditions [14]. The encrypted cysteine was introduced on a 
lysine side chain which after opening under mild conditions with MeONH2 or NH2OH 
resulted in a free cysteine enabling reactions with maleimide groups (Figure 4).
Furthermore, it was shown that this technique is fully compatible with established 
techniques of peptide synthesis and NCL. The chemokine CCL5 was synthesized 
from an N- and C-terminal part that were joined by native chemical ligation. The 
C-terminus contained a lysine with an orthogonal Fmoc protective group. After 
completion of the synthesis of the C-terminus, the Fmoc group was removed and the 
thiazolidine residue was site-specifically introduced. After cleavage from resin and 
Figure 2. 
Conjugation at Nε-amine group of a lysine residue with an amine reactive NHS ester (N-hydroxysuccinimide 
ester) resulting in an amide bond.
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Figure 3. 
Conjugation at a free thiol moiety present in cysteine using a maleimide resulting in a thioether bond.
Figure 5. 
Schematic representation of the synthesis of chemokine CCL5. In the first step two unprotected peptide 
fragments are ligated using native chemical ligation. Subsequently, the peptide is folded into an active protein. 




subsequent purification, the two parts were ligated to obtain the full length protein 
and subsequently the protein was folded under oxidative conditions. After obtaining 
the folded protein, the thiazolidine ring was opened by treatment with MeONH2.
Upon treatment with MeONH2 to convert the thiazolidine functionality into a 
free cysteine and subsequent modification with a maleimide label, unwanted disul-
fide shuffling can occur in proteins containing disulfide bonds [18]. To circumvent 
this problem a synchronized protocol for thiazolidine deprotection and maleimide 
coupling can be best used (Figure 5).
A chemoselective conjugation approach that does not use any of the naturally 
occurring functional groups in proteins is oxime ligation. The reaction is comprised 
of a ketone or aldehyde reacting with an aminooxy group to yield an oxime bond 
(Figure 6). The reaction can be performed in aqueous media at neutral pH but 
is faster at slightly acidic pH [19]. The reaction can be catalyzed with aniline or 
derivatives thereof, to facilitate fast reactions [20, 21].
Although the oxime reaction itself can be performed relatively easy, the more 
challenging part is the incorporation of a ketone or aminooxy in the peptide/
protein of interest. Since a ketone is virtually inert to most chemical reactions, the 
ketone is mostly chosen over the aminooxy component to be incorporated in  
the protein of choice, while the aminooxy component is used to modify the label. 
The increased attention for the oxime bond in the last decade has led to the devel-
opment of several methods to incorporate ketones or aldehydes in proteins. An 
overview of the available techniques was previously reviewed, here we will briefly 
highlight methods useful in chemical synthesis [22]. Historically, oxidation of 
peptides/proteins containing an N-terminal 2-amino alcohol residue (serine/
threonine) is among the most used to obtain an aldehyde in the form of a glyoxy-
loyl moiety [23]. Site-specific incorporation using chemical synthesis, however, 
can be achieved using suitably protected unnatural amino acids such as p-acetyl-
phenylalanine or keto-proline [24, 25]. A large amount of flexibility in both site of 
introduction and distance from active regions can be achieved with modification 
of amine moieties with keto-acids [26, 27]. Care has to be taken, however, in the 
choice of keto-acid as some are less efficient in subsequent oxime formation [28].
In summary, several techniques are available for the modification of proteins to 
include chelators used for PET and SPECT. Amine and thiol reactive compounds 
are easy to use through orthogonally protected lysine side chains or through 
thiazolidine deprotection in pre-folded proteins. Oxime conjugation can be used 
for chelator incorporation but is also used for covalent radiolabeling approaches, 
such as introducing 18F-containing prosthetic groups (see for an overview [29]).
3. Radiolabeling of peptides
A variety of labeling techniques can be applied to peptides and proteins, but 
according to George De Hevesy’s definition of a tracer the radiolabeling procedure 
should not affect the biological properties, the affinity to the target, or the physi-
cochemical properties (e.g. charge, hydrophilicity, size). In the following part a list 
Figure 6. 
Reaction of an aminooxy with a ketone which results in an oxime bond.
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of radiosynthesis techniques for commonly used isotopes is described, omitting 
isotopes that are used less frequently. For example, 11C is a widespread isotope for 
labeling small organic compounds, but it is used less frequently in peptides or larger 
structures and so will therefore not be further discussed here.
3.1 Radioiodination
Radioiodination of peptides with 125I, 123I, 124I, or 131I can be performed by either 
direct labeling or indirect labeling via an auxiliary group. During direct radioiodin-
ation, radioactive iodine is incorporated covalently into the side chains of tyrosyl 
or histidyl residues in the presence of an oxidizing agent such as chloramine-T 
or iodogen. If no tyrosyl or histidyl residue is available, free amino groups in the 
peptide may be radioiodinated by auxiliary groups, including N-succinimidyl-
3-(4-hydroxyphenyl)propionate, known as Bolton-Hunter reagent [30]. Other 
auxiliary groups for radioiodination of peptides are N-succinimidyl-3-iodobenzoate 
(SIB), N-succinimidyl-5-iodo-3-pyridinecarboxylate (SIPC), and N-succinimidyl 
4-guanidinomethyl-3-iodobenzoate (SGMIB) (Figure 7) [31–34].
As none of the radioiodination methods is based on complexation with a chela-
tor, we will not focus on this labeling method in this book chapter further.
3.2 Radiofluorination
For routine PET imaging, fluorine-18 represents the near ideal radionuclide with 
its half-life of 109.8 min and low β+-energy (0.64 MeV). Due to this low positron 
energy, it has a short positron linear range in tissue, leading to particularly high 
spatial resolution in PET imaging. Furthermore, compared to other short lived 
radionuclides, such as 11C, its half-life is long enough to allow syntheses and imag-
ing procedures to be extended over hours, enabling kinetic studies and high-quality 
metabolite and plasma analysis.
Efficient 18F-labeling of peptides and proteins often comprises a multistep pro-
cess involving labeling and purification of a prosthetic group (synthon) and subse-
quent conjugation of the 18F-labeled synthon to the peptide/protein with or without 
activation. If necessary, the 18F-conjugate is purified by a final purification step. 
Over the years, a variety of prosthetic groups have been developed ranging from 
amine-reactive groups such as N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) 
[35] to chemoselective groups like 4-[18F]fluorobenzaldehyde and [18F]FDG ([18F]
Figure 7. 
The auxiliary groups Bolton-hunter reagent, SIB, SIPC, and SGMIB for the radioiodination of peptides.
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fluorodeoxyglucose) [36, 37] that react with an aminooxy- or hydrazine-modified 
peptides. A special prosthetic group approach that has been explored in 18F-labeling 
chemistry is the click chemistry methodology. Click chemistry appeared to be an 
effective method to radiolabel peptides and proteins, because the click reaction 
is fast, bioorthogonal, chemo- and regioselective, results in relatively high yields 
and can be performed in aqueous media. This copper(I)-catalyzed azide-alkyne 
cycloaddition reaction has been exploited in radiopharmaceutical chemistry by 
several research groups [38–44]. A variant of the copper(I)-catalyzed click reaction 
is the copper-free click reaction that does not require the use of the cytotoxic metal. 
Reactions of electron-deficient tetrazines with ring-strained trans-cyclooctenes 
or norbenes have been investigated [45–49]. Click reactions, Cu(I)-catalyzed and 
copper-free, appeared to be powerful and versatile reactions for the synthesis of 
18F-labeled peptides and proteins.
In spite of the variety of possibilities for introducing 18F, a major drawback of the 
18F-labeling methods described above is that they are laborious, (require azeotropic 
drying of the fluoride and multiple purification steps) and are thus time consum-
ing. In search of a kit-based 18F-labeling method, new 18F-labeling strategies based 
on fluorine-silicon [50–56], fluorine-boron [57–59], and fluorine-phosphorus [60] 
have been developed.
A facile chelator-based approach was developed wherein 18F is first attached to 
aluminum as Al18F, which is then complexed in a chelating agent attached to the pep-
tide, forming a stable Al18F–chelate peptide complex in an efficient 1-pot process [61].
3.3 Radiolabeling with 68Ga
Gallium-68 is an interesting positron-emitter, because of its well established 
radiochemistry and its easy access and availability from commercial available 
68Ge/68Ga-generators (t1/2 
68Ge = 268 days) which renders it independent of an on-
site cyclotron. The application of 68Ga-labeled peptides and proteins has attracted 
considerable interest for molecular imaging, because of its physical characteristics. 
The high positron emission fraction, 89% through positron emission of 1.9 MeV 
(max. energy), and half-life of 68 min allows short scanning times with sufficient 
amounts of radioactivity for high quality images. Generally, DOTA and NOTA are 
very suitable chelators and are commonly used for 68Ga3+-complexation. Though, 
recently TRAP (Tri-azacyclononane-phosphinic acid) and its derivatives revealed 
to be powerful 68Ga chelators which possess valuable utility in nuclear medicine and 
molecular imaging [62].
DOTA has a larger cavity than NOTA and, thus, needs higher ring distortion for 
complexation of 68Ga3+. Therefore, higher temperatures are required for 68Ga-DOTA 
complex formation compared to 68Ga complex formation with NOTA. Typically, 
DOTA-conjugated peptides are radiolabeled with 68Ga at 90–100°C, whereas NOTA-
conjugated peptides can be labeled at room temperature [62].
Generally, 68Ga is obtained by eluting a 68Ge/68Ga generator with a 0.01–1 M 
HCl solution. The eluate can be added directly to the NOTA- or DOTA-conjugated 
compound dissolved in a suitable buffer system such as HEPES (4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid), phosphate, or ammonium acetate. It is 
important that the resulting pH of the reaction mixture is a pH value <4 to prevent 
formation of colloidal hydroxide [68Ga(OH)3]n which begins at a pH value above 4.
3.4 Radiolabeling with 111In
The SPECT isotope indium-111 is a frequently used radionuclides in diagnos-
tic nuclear medicine. It has a physical half-life of 67 hours and is produced by a 
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cyclotron. The principle photons are 173 keV (89%) and 247 keV (94%). The most 
commonly used chelators for 111In-labeling of peptides and proteins are DTPA and 
DOTA. DTPA chelates 111In at room temperature with sufficient efficiency and 
stability. This DTPA chelator is used in the commercially available somatostatin 
analog OctreoScan®. DOTA forms a more stable complex with 111In, but requires 
heating of the reaction mixture which can lead to protein denaturation, especially 
for larger proteins. Labeling of DTPA- and DOTA-conjugated peptides and proteins 
is a one pot, one step procedure in which the compound is incubated with 111InCl3 
at a pH between 4 and 6. Ammonium and sodium acetate buffers are commonly 
used as buffer for labeling of DTPA- and DOTA-conjugated compounds with 
111In. However, it was shown that 111In-labeling efficiency and specific activity 
of DTPA- and DOTA-conjugated peptides was significantly improved in MES 
(2-(N-morpholino)ethanesulfonic acid) and HEPES buffer compared to acetate 
buffers [63]. The enhanced labeling efficiency appeared to be due to the reduced 
competitive chelation of cadmium, the decay product of 111In. These observations 
made MES and HEPES the buffers of choice for 111In-labeling.
3.5 Radiolabeling with 99mTc
Technetium-99 m is the most widely used isotope due to its ideal half-life of 
6 hours, its low cost, and excellent imaging characteristics. Similar to 68Ga, 99mTc 
can be obtained from a generator (99Mo/99mTc, with a half-life of 66 hours for 99Mo) 
which is easily shipped, allowing worldwide use. Since the 1960s, 99mTc has been 
used in a variety of applications, including cancer research and cardiac assessment. 
99mTc is a nearly pure gamma-emitter (88%), with the remaining 12% yielding 
internal conversion electrons. The application is therefore restricted to SPECT 
imaging (although research into therapeutic applications is also performed).
Possibilities for coupling of 99mTc to small organic compounds, peptides or 
proteins are nearly unlimited, in part due to the many oxidation states that 99mTc 
can have, ranging from +I to +VII. The isotope is obtained from the generator in a 
pH-neutral and isotonic saline solution, ensuring computability with nearly any 
peptide or protein.
One solution to radiolabel proteins is, instead of chemically modifying the 
protein, synthesizing it with an additional hexa-histidine chain at the N-terminus 
(His-tag). This addition mostly does not interfere with recognition sites and allows 
for site-specific labeling of 99mTc (in the form of 99mTc(CO)3) [64]. This is a two-
step reaction, where 99mTcO4- (Technetium pertechnetate, as it is eluted from the 
generator) is first converted to 99mTc(CO)3 (thereby changing the oxidation state 
from +VII to +I, under relatively harsh conditions) and subsequently coupling 
99mTc(CO)3 to the His-tag.
An alternative for 99mTc-labeling of peptides and proteins is conjugating them 
with the bifunctional chelator HYNIC (6-hydrazinonicotinic acid). HYNIC has 
been introduced to radiolabel an IgG antibody with 99mTc for infection imaging 
[65]. HYNIC is an established and appropriate BCA for 99mTc-labeling, because it 
allows rapid and efficient labeling of proteins. In addition, 99mTc-labeled HYNIC-
conjugates can be produced with high specific activities. However, conjugation of 
HYNIC to a peptide of protein can be complex as the hydrazine group of HYNIC 
is highly nucleophilic and, when unprotected, undergoes unwanted side reac-
tions with electrophiles. Protecting the hydrazine group of HYNIC-conjugated 
compounds with for example Fmoc, Cbz, and Boc, has been investigated by several 
research groups and is still subject of current research [66–71].
Since the HYNIC group can only coordinate to a metal through 2 donor groups 
at most, it is unable to saturate the technetium coordination sphere. To complete 
Radiopharmaceuticals
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the coordination sphere, an additional coligand, such as EDDA (ethylenediamine 
diacetic acid), tricine (N-[Tris(hydroxymethyl)-methyl]glycine), or nicotinic acid 
is required. However, the choice of the coligand has significant influence on the 
pharmacokinetics, and thus, biologic properties of the radiotracer [72]. Because 
the chemistry of HYNIC conjugation to a peptide or protein remains a challenge 
and the coordination mode of the 99mTc-HYNIC complex is still undefined, it is not 
possible to give a standard HYNIC-conjugation and 99mTc-radiolabeling protocol. 
For a review about 99mTc-HYNIC coordination chemistry see Meszaros et al. and 
references herein [73].
4. Conclusions
Improvements in effective nuclear imaging are not only dependent on progres-
sion in imaging equipment and technology, but is also strongly dependent on 
the availability of powerful probes with optimal pharmacokinetic and imaging 
characteristics. The diversity of methods for syntheses of peptides and proteins and 
the variety of possibilities for modification, stabilization, labeling (radiolabeling 
and labeling for other modalities), and construction of more complex multivalent 
and multimodal constructs, make radiolabeled peptides and proteins a flexible 
class of tracers and meaningful molecules for nuclear imaging of several diseases 
such as cancer, thrombosis, infection, and inflammation in pre-clinical and clinical 
research.
Radiotracers enable early diagnosis and thus early treatment of disease and they 
enable better stratification of patients with disease-stage-adapted therapy instead 
of escalating to the most aggressive and costly therapy. Moreover, radiolabeled 
compounds are used to monitor the therapeutic effect of drugs and are used as 
therapeutic radiopharmaceuticals when labeled with either β− - or α-emitting 
radionuclides such as 90Y, 186Re, 188Re, 131I, 177Lu and 211At and 213Bi, respectively.
The growth of the world population and the overall rise in life expectancy in 
the last decades will increase the demand for radiopharmaceuticals, including basic 
research into and the development of new radiopharmaceuticals.
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